Physician profile
Abdullahi I Mubarak
NPI 1861521940
$6,171.42
in general payments reported to CMS, 2019-2025
32 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 90% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $221 · 2021: $671 · 2022: $699 · 2023: $1,083 · 2024: $1,321 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,782.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,501.03 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $964.49 | 2019-2025 | Xtampza, Belbuca |
| Indivior INC. | $480.32 | 2019-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $376.65 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $358.43 | 2019-2025 | Vivitrol, Vivitrol |
| Axsome Therapeutics, INC. | $242.90 | 2023-2025 | Sunosi, Symbravo |
| Orexo US, INC. | $229.09 | 2019-2024 | Zubsolv |
| Biodelivery Sciences International, INC. | $221.31 | 2019-2021 | |
| Pfizer INC. | $214.25 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.17 | 2025 | Caplyta |
| Lundbeck LLC | $163.15 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $154.71 | 2019-2023 | |
| Lilly USA, LLC | $152.97 | 2019-2024 | Mounjaro |
| Nestle Healthcare Nutrition INC. | $146.28 | 2021-2023 | |
| Almatica Pharma LLC | $144.37 | 2024-2025 | Loreev Xr, Teriparatide |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $128.92 | 2023-2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $104.75 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $95.40 | 2024 | Airsupra, Farxiga |
| Aimmune Therapeutics, INC. | $54.86 | 2024-2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company Ltd. | $47.71 | 2022 | |
| Novo Nordisk INC | $37.42 | 2019 | |
| Mdd US Operations, LLC | $26.08 | 2019 | |
| Virtus Pharmaceuticals LLC | $21.34 | 2021 | |
| Kaleo, INC. | $17.88 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.48 | 2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $16.90 | 2021 | |
| Glaxosmithkline, LLC. | $14.98 | 2022 | |
| Protega Pharmaceutials INC | $14.18 | 2023 | Roxybond |
| Scilex Pharmaceuticals INC. | $13.27 | 2019 | |
| Bausch Health US, LLC | $12.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.48 | 2019 | |
| Daiichi Sankyo INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullahi Mubarak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.